PIP Search Page

Displaying 681 - 700 of 961

PIPS Search Results
PIP Number	Active Substance	Conditions / Indications	Invented Name	Therapeutic area	Decision Type	Compliance Check	Date Published Sort ascending
MHRA-100535-PIP01-22-M01 (update)	UMECLIDINIUM BROMIDE FLUTICASONE FUROATE VILANTEROL TRIFENATATE	Treatment of asthma	Trelegy Ellipta Trelegy Ellipta/ Elebrato/Temybric Trelegy Ellipta	Pneumology - Allergology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	07/12/2022
MHRA-100479-PIP01-22-M01 (update)	POSACONAZOLE	Prevention of invasive fungal infections Treatment of invasive fungal infections	Noxafil Noxafil Noxafil Noxafil Noxafil	Infectious diseases	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	07/12/2022
MHRA-100148-PIP01-21-M02 (update)	LENVATINIB MESILATE	Malignant neoplasms except haematopoietic, lymphoid, papillary & follicular thyroid, &osteosarcoma	Lenvima Kisplyx Lenvima Kisplyx	Oncology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	07/12/2022
MHRA-100507-PIP01-22-M01 (update)	BREXPIPRAZOLE	Treatment of schizophrenia	RXULTI RXULTI	Psychiatry	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	07/12/2022
MHRA-100492-PIP01-22-M01 (update)	MOLGRAMOSTIM	Treatment of pulmonary alveolar proteinosis	Not available at present	Pneumology - Allergology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	07/12/2022
MHRA-100476-PIP01-22	Anti-(alpha-synuclein) human monoclonal antibody	Treatment of Multiple System Atrophy Treatment of Parkinson's Disease		Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100481-PIP01-22	TUCATINIB	Treatment of solid tumours	Tukysa	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100404-PIP01-21	insulin icodec SEMAGLUTIDE	Treatment of type 2 diabetes mellitus		Endocrinology-Gynaecology-Fertility-metabolism	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100365-PIP01-21	Batiraxcept	Treatment of Ovarian cancer Treatment of Fallopian tube cancer Treatment of Primary peritoneal cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100395-PIP01-21	TALAZOPARIB TOSYLATE	Treatment of breast malignant neoplasms Treatment of prostate malignant neoplasms	Talzenna Talzenna Talzenna Talzenna Talzenna Talzenna	Psychiatry Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100366-PIP01-21	Cevostamab	Treatment of multiple myeloma		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100383-PIP01-21	TRASTUZUMAB DERUXTECAN	Treatment of lung cancer	Enhertu Enhertu Enhertu	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	07/12/2022
MHRA-100465-PIP01-22-M01 (update)	efanesoctocog alfa	Treatment of congenital haemophilia A		Haematology-Hemostaseology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	07/12/2022
MHRA-100455-PIP01-22-M01 (update)	IXAZOMIB	Treatment of multiple myeloma Treatment of lymphoid malignancies (excluding multiple myeloma)	Ninlaro Ninlaro Ninlaro Ninlaro	Oncology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	07/12/2022
MHRA-100444-PIP01-22-M01 (update)	ETELCALCETIDE	Treatment of hyperparathyroidism	Parsabiv Parsabiv	Uro-Nephrology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	07/12/2022
MHRA-100441-PIP01-22-M01 (update)	Delandistrogene moxeparvovec	Treatment of Duchenne Muscular Dystrophy (DMD)	Elevidys	Neurology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	07/12/2022
MHRA-100412-PIP01-22-M02 (update)	vadadustat	Treatment of anaemia due to chronic disorders	VAFSEO VAFSEO	Haematology-Hemostaseology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	07/12/2022
MHRA-100408-PIP01-21-M01 (update)	Hepatitis B (rDNA) surface antigen adjuvanted	Prevention of hepatitis B virus infection	HEPLISAV B	Vaccines	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	07/12/2022
MHRA-100361-PIP01-21-M01 (update)	GOLIMUMAB	Treatment of ulcerative colitis	Simponi 50 mg solution for injection in pre-filled pen Simponi 50 mg solution for injection in pre-filled syringe Simponi 100 mg solution for injection in pre-filled pen Simponi 45 mg/0.45 mL solution for injection in pre-filled pen Simponi Simponi Simponi Simponi Simponi Simponi Simponi Simponi	Immunology -Rheumatology-Transplantation	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	07/12/2022
MHRA-100333-PIP01-21-M01 (update)	MIRABEGRON	Treatment of neurogenic detrusor overactivity	BETMIGA BETMIGA MYRBETRIQ / MYRBETRIQ GRANULES	Uro-Nephrology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No	07/12/2022

Download XLSX

Search Filters: